Last reviewed 2026-04-23 · How we verify

MCC-TT

MCC-TT is a therapeutic vaccine designed to stimulate immune responses against meningococcal and tetanus pathogens through conjugate technology.

MCC-TT is a therapeutic vaccine designed to stimulate immune responses against meningococcal and tetanus pathogens through conjugate technology. Used for Prevention of meningococcal disease and tetanus.

At a glance

Mechanism of action

MCC-TT combines meningococcal polysaccharide antigens with tetanus toxoid as a carrier protein to enhance immunogenicity and promote T-cell mediated immunity. This conjugate vaccine approach aims to provide protection against meningococcal disease while simultaneously boosting or maintaining tetanus immunity in a single formulation.

Approved indications

• Prevention of meningococcal disease and tetanus

Common side effects

• Injection site reactions (pain, erythema, swelling)
• Fever
• Myalgia
• Fatigue

Key clinical trials

• Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) (PHASE3)
• Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• MCC-TT CI brief — competitive landscape report
• MCC-TT updates RSS · CI watch RSS
• MCM Vaccines B.V. portfolio CI